Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pachyrrizine SCHEMBL31474215 | 1.00 | CYP3A4 (1.00) | CYP3A4HSD17B10CASP1CASP7HTT | |
| Pachyrrizine SCHEMBL29350520 | 1.00 | CYP3A4 (1.00) | CYP3A4HSD17B10CASP1CASP7HTT | |
| SCHEMBL29705675 | 0.80 | HSD17B10 (0.67) | CYP3A4HSD17B10CASP1CASP7ACHE | |
| SCHEMBL1301705 | 0.77 | CYP3A4 (0.62) | CYP3A4HSD17B10CASP1CASP7HTT | |
| SCHEMBL29804577 | 0.71 | CYP3A4 (0.55) | CYP3A4HSD17B10CASP1CASP7CYP2D6 | |
| SCHEMBL18788970 | 0.69 | RAB9A (0.66) | CYP3A4HSD17B10CASP1CASP7HTT | |
| SCHEMBL8936325 | 0.68 | MAOA (0.56) | CYP3A4HSD17B10CASP1CASP7HTT | |
| SCHEMBL3467047 | 0.67 | CYP3A4 (0.59) | CYP3A4HSD17B10CASP1CASP7HTT | |
| SCHEMBL4283565 | 0.66 | SMN1; SMN2 (0.51) | CYP3A4HSD17B10CASP1CASP7ACHE | |
| SCHEMBL4580168 | 0.66 | MCL1 (0.55) | CYP3A4HSD17B10CASP1CASP7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20160151390-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3025714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9233107-B2 | Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) | BIOGEN MA INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | CYP3A4 573/4885HSD17B10 697/4885CASP1 3476/4885 |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | TYR, MC1R, MITF | CYP3A4 809/4885HSD17B10 112/4885CASP1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.